New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies

Life

Paolo Falvo¹  Giulia Mitola¹  Francesco Bertolini¹ 

[1] Laboratory of Hematology-Oncology, IEO European Institute of Oncology IRCCS, 16, 20139 Milan, Italy;

关键词: tumor resistance;    in vitro and in vivo studies;    preclinical studies;   

DOI  :  10.3390/life11111131

来源: DOAJ

【 摘 要 】

Disease relapse caused by drug resistance still represents a major clinical hurdle in cancer treatments. Tumor cells may take advantage of different intracellular and genetic systems attenuating the drug effects. Resistant cells or minimal residual disease (MRD) cells have strong clinical relevance, as they might give rise to secondary tumors when the therapy is concluded. Thus, MRDs are crucial therapeutic targets in order to prevent tumor relapse. Therefore, several groups aim at understanding how MRDs are orginated, characterizing their molecular features, and eradicating them. In this review, we will describe MRD from a genetic, evolutionary, and molecular point of view. Moreover, we will focus on the new in vitro, in vivo, preclinical, and clinical studies that aim at eradicating tumor resistance.

【 授权许可】

Unknown